Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The NIHR has invested £34 million of funding into global health research projects to tackle epilepsy, infection-related cancers and severe stigmatising skin diseases in low- and middle-income countries (LMICs).

The NIHR Research and Innovation for Global Health Transformation (RIGHT) programme has awarded Official Development Assistance (ODA) funding to eight projects led by teams made up of researchers in the UK and those in LMICs.

Professor Anna Schuh from the Department of Oncology is leading one of the eight projects, and will be investigating two new techniques to diagnose Epstein-Barr virus, a common cause of blood cancers in sub-Saharan Africa. Her research in Tanzania and Uganda aims to speed up diagnosis and treatment of the infection, reducing the mortality rate from these cancers.

 

For more information on the full recipients of funding for this programme grant, please go to https://www.nihr.ac.uk/news/nihr-invests-34-million-into-global-health-research-on-epilepsy-infection-related-cancers-and-severe-stigmatising-skin-diseases/22764

Similar stories

Further funding secured to hunt out cancer using innovative radiotherapy techniques

Funding Research

Initial success leads to new award for Oxford researcher pushing forward new cancer-hunting radiotherapy despite lockdown.

Reprogramming tumour cells using an antimalarial drug

Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.

Hidden lung damage from COVID-19 revealed in new study

Research Translational Research

Early findings from a study into longer-term damage amongst patients recovering from COVID-19 suggest that the use of cutting-edge scanning techniques may detect previously unseen lung damage.

Oxfordshire-based SCAN pathway wins BMJ award

Innovation Research

A pathway designed to investigate individuals with non-specific but concerning symptoms of cancer wins the BMJ Awards 2020 Cancer Care Team of the Year.